News Center

• Sep. 15

  2026

  VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED BREAKTHROUGH THERAPY DESIGNATION BY NMPA IN CHINA FOR THE TREATMENT OF PATIENTS WITH ACTIONABLE GENOMIC ALTERATION-NEGA

• Sep. 14

  2026

  VOLUNTARY ANNOUNCEMENT - PHASE I/II CLINICAL TRIAL DATA OF SYS6010 IN COMBINATION WITH ENLONSTOBART FOR THE TREATMENT OF SYSTEMIC TREATMENT-NAIVE, ACTIONABLE GE

• Sep. 09

  2026

  VOLUNTARY ANNOUNCEMENT - GOSERELIN SUSTAINED-RELEASE INJECTION (SYH9102 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

• Sep. 08

  2026

  VOLUNTARY ANNOUNCEMENT - INNOVATIVE CHEMICAL DRUG SYH2083 EYE DROPS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA

• Sep. 07

  2026

  VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYH2085 TABLETS FOR THE TREATMENT OF UNCOMPLICATED INFLUENZA IN ADULTS OFFICIALLY INITIATED IN CHINA

• Sep. 01

  2026

  VOLUNTARY ANNOUNCEMENT - SYS6010 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA IN CHINA FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATI